Sanitas, Inc., a privately held company developing mobile and web solutions for outpatients with chronic conditions, has received approval from the US Food and Drug Administration, (FDA) as a 510(K) class II medical device for Wellaho, its proprietary mobile and web platform.

Wellaho's Personalized Outpatient Management System- currently deployed in a number of clinical studies at UC San Diego Health Services - is a physician-directed, web-based and mobile platform that allows providers to supervise and monitor patients between office visits in a secure, HIPAA compliant environment, while enabling patients to access their medical information, monitor their condition, stream relevant educational materials and connect securely to their doctors and healthcare team.

Naser Partovi, CEO of Sanitas, Inc., said of the Wellaho system, "Patients with chronic conditions need a web of care, coming from the best that providers and technology can offer. Given the tsunami of new apps and technologies that hit the market each year, both patients and providers need the highest validation for the products and services they use. Now, with the FDA's approval, Wellaho offers one more reason for providers and patients to trust that we can provide a safe, secure, and effective solution for managing their care."

Sanitas Inc. is a privately held San Diego company founded in 2010. Wellaho is the company's proprietary web and mobile platform serving patients with chronic conditions including: diabetes, congestive heart failure, kidney disease, COPD, asthma, hypertension, breast cancer, sleep disordered breathing, and obesity.